{
  "meta": {
    "timestamp": "2025-01-06T12:47:08.045363",
    "version": "1.0",
    "type": "search_analysis"
  },
  "companies": [
    {
      "company_name": "MaxCyte Inc",
      "symbol": "MXCT",
      "analysis": {
        "historical": {
          "risk_score": 50,
          "key_risks": [
            "Regulatory risks due to dependence on unpredictable approvals for cell-based therapies",
            "Increasing competition from alternative cell-engineering platforms and viral delivery systems",
            "Challenges in market adoption of non-viral technologies",
            "Economic sensitivity to downturns affecting R&D budgets of biopharmaceutical partners",
            "Potential governance and strategic shifts due to changes in major shareholdings"
          ],
          "controversies": [
            "Potential legal disputes arising from IP enforcement activities",
            "Governance and shareholder dynamics influenced by major stake changes, such as BlackRock's increased stake"
          ],
          "environmental_issues": [],
          "social_issues": [
            "Efforts to improve patient access to lifesaving cell therapies, particularly for chronic disease patients"
          ],
          "governance_issues": [
            "Recent changes in major shareholdings could impact governance and stakeholder dynamics"
          ],
          "recommendation": "caution",
          "confidence_score": 75
        },
        "evidence": {
          "sources": [
            {
              "url": "",
              "title": "Legal Disclaimer | MaxCyte",
              "snippet": "It is MaxCyte's policy to enforce its intellectual property rights to the extent as set forth in applicable laws, including pursuing available criminal sanctions. Unless otherwise indicated, the trademarks, logos and service marks (collectively the Trademarks) displayed on this site are Trademarks owned or licensed by MaxCyte or its partners ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "MaxCyte Inc MaxCyte Inc intellectual property disputes",
              "retrieved_at": "2025-01-06T19:46:41.311197+00:00",
              "published_date": null,
              "source_hash": "ed65bfbf7ba3f393b927ff95928ec374"
            },
            {
              "url": "",
              "title": "MaxCyte, Inc. 202 Annual R eport",
              "snippet": "This is the third annual report of MaxCyte, Inc. ( MaxCyte or the Company ) following the lis ng of our common stock on the Nasdaq Global Select Market in July 2021, and the \u00de rst to be issued since ... The pla orm is also supported by a robust intellectual property por olio with more than 150 granted U.S. and foreign patents and more than 95 ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "MaxCyte Inc MaxCyte Inc intellectual property disputes",
              "retrieved_at": "2025-01-06T19:46:41.311311+00:00",
              "published_date": null,
              "source_hash": "b2315c65eca56f6ff1e5717c80587239"
            },
            {
              "url": "",
              "title": "David Sandoval Email & Phone Number | MaxCyte, Inc. SVP, General ...",
              "snippet": "2023 - 2024 SVP, Legal and Deputy General Counsel @ MaxCyte, Inc. 2010 - 2023 Chief Legal Officer and Head of Legal Affairs and Chief Compliance Officer @ Leadiant Biosciences, Inc. see more ... Intellectual Property at MaxCyte, Inc. Gaithersburg, MD, US View. 4 gmail.com; maxcyte.com; yahoo.com; aol.com; 5 ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "MaxCyte Inc MaxCyte Inc intellectual property disputes",
              "retrieved_at": "2025-01-06T19:46:41.311332+00:00",
              "published_date": null,
              "source_hash": "0d49fa6654956e7170136e5a96688ad1"
            },
            {
              "url": "",
              "title": "Investor Relations | MaxCyte Inc",
              "snippet": "At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "MaxCyte Inc MaxCyte Inc intellectual property disputes",
              "retrieved_at": "2025-01-06T19:46:41.311345+00:00",
              "published_date": null,
              "source_hash": "6c85de60f217fd6368abe4782fcb08f8"
            },
            {
              "url": "",
              "title": "MaxCyte, A World Intellectual Property Organization Trademark of ...",
              "snippet": "MaxCyte is a WIPO trademark and brand of MaxCyte, Inc., 9713 Key West Ave. , Suite 400, Rockville MD 20850,UNITED STATES. This trademark was filed to WIPO on Friday, July 16, 2021. The MaxCyte is under the trademark classification: Pharmaceutical Products; Computer Product, Electrical & Scientific Products; Medical Instrument Products; Education and Entertainment Services; Computer & Software ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "MaxCyte Inc MaxCyte Inc intellectual property disputes",
              "retrieved_at": "2025-01-06T19:46:41.311356+00:00",
              "published_date": null,
              "source_hash": "0bfb4f46ba50498c0a3dc3d3bde44fb7"
            },
            {
              "url": "",
              "title": "Total Voting Rights, 2 Jan 2025 17:53 | Shares Magazine",
              "snippet": "MaxCyte, Inc. (\"MaxCyte\" or the \"Company\") Total Voting Rights ROCKVILLE, MD, January 2, 2025: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, announces that pursuant to ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "MaxCyte Inc MaxCyte Inc intellectual property disputes",
              "retrieved_at": "2025-01-06T19:46:41.311367+00:00",
              "published_date": null,
              "source_hash": "52759c8bdd92cc6fa0edbcd8724f2ec3"
            },
            {
              "url": "",
              "title": "MaxCyte Signs Strategic Platform License Agreement with Legend Biotech ...",
              "snippet": "MaxCyte, Inc., Q3 2024 Earnings Call, Nov 06, 2024 Nov. 06: MaxCyte, Inc. Updates Revenue Guidance for the Full Year 2024 Nov. 06: CI MaxCyte, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 Nov. 06",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "MaxCyte Inc MaxCyte Inc intellectual property disputes",
              "retrieved_at": "2025-01-06T19:46:41.311379+00:00",
              "published_date": null,
              "source_hash": "75514d4aa21bf5de6d8a95d4fb1f98f5"
            },
            {
              "url": "",
              "title": "MaxCyte, Inc. - Exercise of options and PDMR dealing",
              "snippet": "ROCKVILLE - MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, announces that on 26 December 2024, as per a filing lodged with the U.S. Securities and Exchange Commission ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "MaxCyte Inc MaxCyte Inc intellectual property disputes",
              "retrieved_at": "2025-01-06T19:46:41.311389+00:00",
              "published_date": null,
              "source_hash": "2410477442781a59aec4903c7dc1047a"
            },
            {
              "url": "",
              "title": "Patents Assigned to MAXCYTE, Inc. - Justia Patents Search",
              "snippet": "Abstract: The present invention relates to the transient modification of cells. In particular embodiments, the cells are immune systems, such as PBMC, PBL, T (CD3+ and/or CD8+) and Natural Killer (NK) cells. The modified cells provide a population of cells that express a genetically engineered chimeric receptor which can be administered to a patient therapeutically.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "MaxCyte Inc MaxCyte Inc intellectual property disputes",
              "retrieved_at": "2025-01-06T19:46:41.311401+00:00",
              "published_date": null,
              "source_hash": "22f46231c80b7c26c72e4e527c4d62d9"
            },
            {
              "url": "",
              "title": "MaxCyte Regulatory News. Live MXCT RNS. Regulatory News Articles for ...",
              "snippet": "MaxCyte, Inc. (\"MaxCyte\" or the \"Company\") Total Voting Rights ROCKVILLE, MD, January 2, 2025: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "MaxCyte Inc MaxCyte Inc regulatory compliance issues",
              "retrieved_at": "2025-01-06T19:46:45.507237+00:00",
              "published_date": null,
              "source_hash": "66b9c77556c61599154e6ec482fe8b41"
            },
            {
              "url": "",
              "title": "MaxCyte Expands Common Stock Issuance to 105.7 Million Shares",
              "snippet": "An update from MaxCyte ( (MXCT) ) is now available.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "MaxCyte Inc MaxCyte Inc intellectual property disputes",
              "retrieved_at": "2025-01-06T19:46:43.764791+00:00",
              "published_date": "2025-01-02T17:57:00+00:00",
              "source_hash": "ff2f0aa4d106a9342b0648ba264444e4"
            },
            {
              "url": "",
              "title": "MaxCyte Announces Board Member Retirement",
              "snippet": "Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks The latest update is out from MaxCyte ( (MXCT) ).",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "MaxCyte Inc MaxCyte Inc intellectual property disputes",
              "retrieved_at": "2025-01-06T19:46:43.764895+00:00",
              "published_date": "2024-12-23T07:11:00+00:00",
              "source_hash": "0a6e97809432d030d76374a426eaa1a4"
            },
            {
              "url": "",
              "title": "MaxCyte Announces Change in Major Shareholdings",
              "snippet": "MaxCyte, Inc., a company in the biotechnology industry, has announced a change in the major holdings of its shares. The notification indicates that BlackRock, Inc. has acquired and now holds a ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "MaxCyte Inc MaxCyte Inc regulatory compliance issues",
              "retrieved_at": "2025-01-06T19:46:47.755427+00:00",
              "published_date": "2024-12-10T17:17:00+00:00",
              "source_hash": "836fc259138fb783c2ef14763fb9c529"
            },
            {
              "url": "",
              "title": "MaxCyte, Inc.'s (LON:MXCT) Intrinsic Value Is Potentially 72% Above Its Share Price",
              "snippet": "which is 15% above our fair value estimate How far off is MaxCyte, Inc. (LON:MXCT) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "MaxCyte Inc MaxCyte Inc controversies in clinical trials",
              "retrieved_at": "2025-01-06T19:46:51.802213+00:00",
              "published_date": "2025-01-01T05:41:00+00:00",
              "source_hash": "05b74b4ed42235f10a98159e7f11c0ab"
            },
            {
              "url": "",
              "title": "MaxCyte director sells shares after option exercise",
              "snippet": "backed by a global intellectual property portfolio. The information for this report is based on a press release statement from MaxCyte, Inc. This article was generated with the support of AI and ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "MaxCyte Inc MaxCyte Inc intellectual property disputes",
              "retrieved_at": "2025-01-06T19:46:43.764974+00:00",
              "published_date": "2024-12-31T02:04:00+00:00",
              "source_hash": "5b64147ae51c83bb756dca05f093ddf5"
            },
            {
              "url": "",
              "title": "MaxCyte Streamlines Operations and Raises Guidance | MaxCyte Inc",
              "snippet": "By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on X and LinkedIn. MaxCyte Contacts: US IR Adviser. Gilmartin Group. David Deuchler, CFA +1 415-937-5400. ir@maxcyte.com",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "MaxCyte Inc MaxCyte Inc regulatory compliance issues",
              "retrieved_at": "2025-01-06T19:46:45.507031+00:00",
              "published_date": null,
              "source_hash": "8ffc841aa1fc8886f59eb323e791418a"
            },
            {
              "url": "",
              "title": "Documents & Charters - MaxCyte Inc",
              "snippet": "Corporate Governance & Internal Controls. The Directors are committed to maintaining high standards of corporate governance. MaxCyte, as far as appropriate for a company located in the U.S. and of its size and stage of development, adopted the Quoted Companies Alliance Corporate Governance Code (the \"QCA Code\").The Company has adopted an appropriate share dealing code in order to comply ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "MaxCyte Inc MaxCyte Inc regulatory compliance issues",
              "retrieved_at": "2025-01-06T19:46:45.507146+00:00",
              "published_date": null,
              "source_hash": "ea73f88b301c2b3afc7b150577446a8c"
            },
            {
              "url": "",
              "title": "MaxCyte Streamlines Operations and Raises Guidance",
              "snippet": "By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on X and LinkedIn. MaxCyte Contacts: US IR Adviser. Gilmartin Group. David Deuchler, CFA +1 415-937-5400. ir@maxcyte.com ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "MaxCyte Inc MaxCyte Inc regulatory compliance issues",
              "retrieved_at": "2025-01-06T19:46:45.507164+00:00",
              "published_date": null,
              "source_hash": "51846cedf86e2a31611a471983b9cd57"
            },
            {
              "url": "",
              "title": "Technical and Regulatory Support - MaxCyte",
              "snippet": "At MaxCyte \u00ae, we know that bringing a therapy to market requires more than innovative technology.It requires the know-how of experienced professionals to help navigate challenges along the way. This is why our team works closely with our partners, leveraging our technical and regulatory expertise to help chart your best course forward from discovery to commercialization.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "MaxCyte Inc MaxCyte Inc regulatory compliance issues",
              "retrieved_at": "2025-01-06T19:46:45.507179+00:00",
              "published_date": null,
              "source_hash": "42dd31b8ccbf148ab1d2870f702ec169"
            },
            {
              "url": "",
              "title": "MaxCyte, Inc. 202 Annual R eport",
              "snippet": "opportunity and regulatory backdrop for cell therapies con nues to improve. We con nue to lay the groundwork for long-term growth at MaxCyte, just as we did several years ago with CRISPR to support what is now Casgevy. In 2023, we signed \u00de ve new SPL clients, bringing the total number of SPLs to 23 as of December 31, 2023.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "MaxCyte Inc MaxCyte Inc regulatory compliance issues",
              "retrieved_at": "2025-01-06T19:46:45.507197+00:00",
              "published_date": null,
              "source_hash": "a7b605dd66c52027e2d456f71af0b644"
            },
            {
              "url": "",
              "title": "MaxCyte Announces Change in Shareholder Voting Rights Due to ... - Nasdaq",
              "snippet": "MaxCyte ( ) has shared an update. MaxCyte has announced a change in its shareholder voting rights as BlackRock, Inc. adjusted its holdings, crossing a regulatory threshold.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "MaxCyte Inc MaxCyte Inc regulatory compliance issues",
              "retrieved_at": "2025-01-06T19:46:45.507211+00:00",
              "published_date": null,
              "source_hash": "b3d749ffc93067484cc1f17a133acbef"
            },
            {
              "url": "",
              "title": "MaxCyte, Inc. ESG Risk Rating - Sustainalytics",
              "snippet": "MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "MaxCyte Inc MaxCyte Inc regulatory compliance issues",
              "retrieved_at": "2025-01-06T19:46:45.507223+00:00",
              "published_date": null,
              "source_hash": "43f67938f013d505de6a9a022f19de11"
            },
            {
              "url": "",
              "title": "Director, Regulatory Affairs - Rockville - MaxCyte Inc - beBee",
              "snippet": "The Director, Regulatory Affairs at MaxCyte leads the Regulatory function, developing and implementing regulatory compliance strategies to meet business needs, safety, quality, and regulatory requirements. \u00b7 Key Responsibilities: \u00b7 Interprets regulations to support cross-function ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "MaxCyte Inc MaxCyte Inc regulatory compliance issues",
              "retrieved_at": "2025-01-06T19:46:45.507248+00:00",
              "published_date": null,
              "source_hash": "b66dd630b157e21363987f6fc720e66e"
            },
            {
              "url": "",
              "title": "Regulatory Affairs Leader for MaxCyte - Rockville - MaxCyte Inc",
              "snippet": "The Director, Regulatory Affairs will lead the Regulatory function at MaxCyte. This role develops and implements regulatory compliance and strategies to meet business needs as well as safety, quality, and regulatory requirements. \u00b7 Job Responsibilities: \u00b7 Interprets regulations, ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "MaxCyte Inc MaxCyte Inc regulatory compliance issues",
              "retrieved_at": "2025-01-06T19:46:45.507261+00:00",
              "published_date": null,
              "source_hash": "0ad0838b63d419238a98d9892f63d85d"
            },
            {
              "url": "",
              "title": "MaxCyte Announces Change in Shareholder Voting Rights Due to BlackRock Holdings",
              "snippet": "MaxCyte has announced a change in its shareholder voting rights as BlackRock, Inc. adjusted its holdings, crossing a regulatory threshold. This adjustment, involving both direct and indirect voting rights, reflects BlackRock's continued interest in MaxCyte, potentially impacting the company's governance and stakeholder dynamics.",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "MaxCyte Inc MaxCyte Inc controversies in clinical trials",
              "retrieved_at": "2025-01-06T19:46:51.802314+00:00",
              "published_date": "2024-12-19T16:32:00+00:00",
              "source_hash": "b47cfb6b2fa4bf12a1309597eb4a3bd1"
            },
            {
              "url": "",
              "title": "Maxcyte Announces Streamlined Operations And Raises 2024 Revenue Guidance",
              "snippet": "Dec. 08, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT ... as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "MaxCyte Inc MaxCyte Inc regulatory compliance issues",
              "retrieved_at": "2025-01-06T19:46:47.755455+00:00",
              "published_date": "2024-12-09T02:02:00+00:00",
              "source_hash": "c3ebb676b783407a757ae93bee317143"
            },
            {
              "url": "",
              "title": "MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics",
              "snippet": "Nov. 13, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT ... as well as scientific, technical and regulatory support, to develop biomedical innovations that will transform human health.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "MaxCyte Inc MaxCyte Inc regulatory compliance issues",
              "retrieved_at": "2025-01-06T19:46:47.755501+00:00",
              "published_date": "2024-11-13T00:00:00+00:00",
              "source_hash": "840a0ce2e2716b3787b02bfdd49bc5be"
            },
            {
              "url": "",
              "title": "MaxCyte Minutes Newsletter - Q4 2024",
              "snippet": "Our joint efforts will enable support SSCI's Advanced Therapy Center (A TC) to translate lifesaving engineered cell therapies into clinical trials, making them more accessible for chronic disease patients in Southern California. The collaboration will also train researchers on the use of our ExPERT\u2122 transfection platform, a clinically ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "MaxCyte Inc MaxCyte Inc controversies in clinical trials",
              "retrieved_at": "2025-01-06T19:46:49.293672+00:00",
              "published_date": null,
              "source_hash": "489bfc48641c417a18772c3b6f26e9af"
            },
            {
              "url": "",
              "title": "MaxCyte Advances Phase I Clinical Trial | MaxCyte Inc",
              "snippet": "Released : October 24, 2019 07:00 RNS Number : 9395Q MaxCyte, Inc. 24 October 2019 MaxCyte, Inc. (\"MaxCyte\" or the \"Company\") MaxCyte Advances Phase I Clinical Trial of Lead CARMA\u2122 mRNA-based Cell Therapy to Third Cohort of Patients MCY-M11 is being evaluated in relapsed/refractory",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "MaxCyte Inc MaxCyte Inc controversies in clinical trials",
              "retrieved_at": "2025-01-06T19:46:49.293868+00:00",
              "published_date": null,
              "source_hash": "1d53255353299f35ae7433d9061f9134"
            },
            {
              "url": "",
              "title": "MaxCyte, Inc. - Drug pipelines, Patents, Clinical trials - Synapse",
              "snippet": "Sept. 15, 2024 -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, and Kamau Therapeutics, a clinical-stage stem cell ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "MaxCyte Inc MaxCyte Inc controversies in clinical trials",
              "retrieved_at": "2025-01-06T19:46:49.293933+00:00",
              "published_date": null,
              "source_hash": "1c549f5e0e5dc45e244d80e5653e45e2"
            },
            {
              "url": "",
              "title": "Dosing Begins in First Clinical Trial of MCY-M11 | MaxCyte Inc",
              "snippet": "Released : October 10, 2018 07:00 RNS Number : 4884D MaxCyte, Inc. 10 October 2018 MaxCyte, Inc. (\"MaxCyte\" or the \"Company\") MaxCyte Commences Dosing in First Clinical Trial in Solid Tumours First patient dosed in Phase I clinical study to evaluate MaxCyte's lead CAR therapeutic in",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "MaxCyte Inc MaxCyte Inc controversies in clinical trials",
              "retrieved_at": "2025-01-06T19:46:49.293948+00:00",
              "published_date": null,
              "source_hash": "41f3d995d44f40e1521e3b6252496e1e"
            },
            {
              "url": "",
              "title": "CAR-T Cell Therapy Market Research 2024-2025: Navigating - GlobeNewswire",
              "snippet": "CAR-T CLINICAL TRIAL LANDSCAPE 8.1 Most Addressed Indications in Clinical Trials ... Lyell Immunopharma, Inc. March Biosciences; MaxCyte, Inc. Minerva Biotechnologies Corporation; Mustang Bio;",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "MaxCyte Inc MaxCyte Inc controversies in clinical trials",
              "retrieved_at": "2025-01-06T19:46:49.293960+00:00",
              "published_date": null,
              "source_hash": "18d0cfb70d828d4b981cd527a0520481"
            },
            {
              "url": "",
              "title": "MaxCyte Advances Phase I Clinical Trial of Lead CARMA\u2122 mRNA-based Cell ...",
              "snippet": "MaxCyte's wholly-owned lead CARMA candidate, MCY-M11, is currently being evaluated in a Phase I clinical trial in patients with advanced ovarian cancer and peritoneal mesothelioma.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "MaxCyte Inc MaxCyte Inc controversies in clinical trials",
              "retrieved_at": "2025-01-06T19:46:49.293970+00:00",
              "published_date": null,
              "source_hash": "1560f428a1076b5d556a6eb964172cc7"
            },
            {
              "url": "",
              "title": "2020 Full Year Results | MaxCyte Inc",
              "snippet": "MaxCyte Inc. + 1 301 944 1660. ... shrinkage in customer capital budgets or delays in customers' clinical trials, the pandemic could have a material adverse effect on the Company's business, results of operations, financial condition and cash flows. In 2020, the Company made adjustments to its operating, sales and marketing practices to ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "MaxCyte Inc MaxCyte Inc controversies in clinical trials",
              "retrieved_at": "2025-01-06T19:46:49.293983+00:00",
              "published_date": null,
              "source_hash": "d09daf6b0e05d2e97e487c19d7eb952b"
            },
            {
              "url": "",
              "title": "MaxCyte and Wugen Sign Strategic Platform License to Expedite ... - Nasdaq",
              "snippet": "--MaxCyte, Inc.,, a leading cell ... a CD7 targeted CAR-T cell therapy, in a global Phase 1/2 clinical trial for the treatment of relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "MaxCyte Inc MaxCyte Inc controversies in clinical trials",
              "retrieved_at": "2025-01-06T19:46:49.293994+00:00",
              "published_date": null,
              "source_hash": "f5d66cec0113db86544160366cf7ae52"
            },
            {
              "url": "",
              "title": "MaxCyte: Still Bullish Despite Soft Q2 Earnings - Seeking Alpha",
              "snippet": "MaxCyte Q2 Financial Highlights (MaxCyte) Digging into the financials, MaxCyte's gross margin for Q2 2023 came out to 85%, down from 88% in Q2 of last year, partly affected by enlarged in-house ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "MaxCyte Inc MaxCyte Inc controversies in clinical trials",
              "retrieved_at": "2025-01-06T19:46:49.294003+00:00",
              "published_date": null,
              "source_hash": "3dd34ac283f7f65e2e6d0ff0e87b8274"
            },
            {
              "url": "",
              "title": "CAR-T Cell Therapy Market Research 2024-2025: Size, Forecasts, Trials ...",
              "snippet": "CAR-T CLINICAL TRIAL LANDSCAPE. 8.1 Most Addressed Indications in Clinical Trials. 8.2 Current Focus of Ongoing Clinical Trials. 8.3 Clinical Trial by Country. ... MaxCyte, Inc. Minerva Biotechnologies Corporation; Mustang Bio; Noile-Immune Biotech; Novartis AG; Oncternal Therapeutics; Oxford Biomedica plc;",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "MaxCyte Inc MaxCyte Inc controversies in clinical trials",
              "retrieved_at": "2025-01-06T19:46:49.294012+00:00",
              "published_date": null,
              "source_hash": "fd24a3a5bbee859a1a7e2f4d4e68e442"
            },
            {
              "url": "",
              "title": "MaxCyte, Inc. (MXCT)",
              "snippet": "Dec. 22, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq ... Kamau Therapeutics will gain non-exclusive research, clinical and commercial rights to utilise MaxCyte's Flow Electroporation ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "MaxCyte Inc MaxCyte Inc controversies in clinical trials",
              "retrieved_at": "2025-01-06T19:46:51.802346+00:00",
              "published_date": "2024-12-30T00:00:00+00:00",
              "source_hash": "884a588459a4e195c8e074c3fab58156"
            },
            {
              "url": "",
              "title": "MaxCyte, Inc. Announces Change in Major Holdings by BlackRock",
              "snippet": "MaxCyte, Inc. has announced a shift in its major holdings, with BlackRock, Inc., a significant shareholder, adjusting its voting rights in the company. BlackRock's holdings now represent 8.44% ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "MaxCyte Inc MaxCyte Inc controversies in clinical trials",
              "retrieved_at": "2025-01-06T19:46:51.802370+00:00",
              "published_date": "2024-12-10T17:24:00+00:00",
              "source_hash": "4a15b57df28eee88098dbda4eaec362f"
            },
            {
              "url": "",
              "title": "MaxCyte Streamlines Workforce and Boosts Revenue Outlook",
              "snippet": "Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks MaxCyte, Inc. has streamlined operations, resulting in a 15% reduction in its workforce, to enhance efficiency ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "MaxCyte Inc MaxCyte Inc controversies in clinical trials",
              "retrieved_at": "2025-01-06T19:46:51.802394+00:00",
              "published_date": "2024-12-18T14:14:00+00:00",
              "source_hash": "a044db69a495cb4fed3447fb5dc73b47"
            }
          ],
          "queries": [
            {
              "category": "financial_legal",
              "query": "MaxCyte Inc intellectual property disputes",
              "rationale": "Investigate potential legal challenges or disputes related to its proprietary Flow Electroporation\u00ae technology",
              "priority": 1
            },
            {
              "category": "financial_legal",
              "query": "MaxCyte Inc regulatory compliance issues",
              "rationale": "Examine any history of non-compliance or delays with FDA, EMA, or other regulatory bodies",
              "priority": 2
            },
            {
              "category": "ethical_social",
              "query": "MaxCyte Inc controversies in clinical trials",
              "rationale": "Identify any ethical concerns or controversies related to its partnered clinical-stage programs",
              "priority": 3
            }
          ]
        },
        "categorization": {
          "product_issues": [],
          "conduct_issues": [],
          "tags": [],
          "patterns": {}
        }
      },
      "metadata": {
        "analysis_timestamp": "2025-01-06T12:47:08.045371",
        "data_confidence": 75,
        "pattern_confidence": null
      }
    }
  ]
}